en.Wedoany.com Reported - Global contract development and manufacturing organization Jabil announced a non-exclusive strategic collaboration with Switzerland-based HSE AG. This partnership combines Jabil's global medical manufacturing capabilities with HSE's dedicated expertise in the development of life sciences and diagnostic instruments. By integrating product design and manufacturing considerations from the early development stages, the collaboration aims to streamline the transition to scalable production, comprehensively enhancing the industrial automation manufacturing efficiency of medical devices.
Diagnostic companies are outsourcing production to reduce costs and maximize internal capacity. Mike Mahaz, Senior Vice President of Jabil's Global Business Units, stated that through this collaboration, both parties can help clients build resilient supply chains and shorten the time-to-market for next-generation diagnostic instruments. According to market reports, the global clinical diagnostics market is projected to reach approximately $169.23 billion by 2030, with instrument products accounting for nearly half of the share. This provides a vast market space for in-depth collaboration between the two parties in the fields of precision assembly and automated production.
To further strengthen its technical support in the life sciences sector, Jabil recently opened a Catheter Development Laboratory at its Florida headquarters. This lab focuses on engineering prototyping and new product introduction for advanced catheters and medical devices. Such R&D investments targeting precision assembly requirements not only enhance the production accuracy of complex interventional medical devices but also demonstrate the company's strategic supporting role within the high-end medical device supply chain, further solidifying its industrial automation technology foundation.
Jabil plans to gradually close its Clinton, Massachusetts facility by November 2026 and consolidate related production functions into its Devens plant. This consolidation initiative aims to optimize resource allocation and improve the company's overall efficiency in the complex medical instrument manufacturing field. Although some injection molding operations will be relocated, core technology subsidiaries will continue to operate at the original site to ensure the stability of the production chain.
Jabil and HSE will jointly address the challenges in manufacturability and sustainability faced by the diagnostics industry. This deep integration from design inception to mass production not only elevates the precision assembly level of sophisticated medical instruments but also sets a new standard for the application of industrial automation manufacturing in the highly regulated medical field. It aids diagnostic companies in more efficiently translating innovative technologies into clinical application outcomes.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
